Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P980041/S051

Access AFP (on DxI 9000 Analyzer)

BECKMAN COULTER, INC. · Decision date Nov 3, 2025

FDA DECISIONP980041/S051

What did the FDA approve?

FDA records P980041/S051 as a supplement to PMA P980041, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Nov 3, 2025.

FDA approval order statement

migration of the Access AFP to the DxI 9000 Access Immunoassay Analyzer.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Immunology
Decision date
Nov 3, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P980041/S051
Regulatory pathway
PMA supplement
Product code
LOK
Decision code
APPR
Decision date
Nov 3, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS.

Product code
LOK
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P980041/S051 received

    Application receipt date recorded by FDA.

  2. P980041/S051 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P980041. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code LOK

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.PMA supplementSep 22, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 20, 2026FDA
IMMULITE 2000 AFPP010007/S026
Siemens Healthcare Diagnostics, Inc.PMA supplementJul 27, 2026FDA
ABBOTT LABORATORIESPMA supplementMay 11, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementMay 11, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

BECKMAN COULTER, INC.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
250 S. Kraemer Blvd. M/S, W-110, Brea, CA, 92822

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records